

Can clinical risk factors predict functional recovery in ischemic stroke patients with pre-stroke depression?

Leah Wormack

University of South Carolina School of Medicine Greenville

Brice Blum

University of South Carolina School of Medicine Greenville

Benjamin Bailes

University of South Carolina School of Medicine Greenville

Thomas Nathaniel (✉ nathanit@greenvillemed.sc.edu)

University of South Carolina School of Medicine Greenville Campus <https://orcid.org/0000-0003-0954-5050>

Research article

Keywords: Ambulation, Ischemic stroke, pre-stroke depression, recombinant tissue plasminogen activator (rtPA)

Posted Date: June 5th, 2019

DOI: <https://doi.org/10.21203/rs.2.10087/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background. Specific clinical risk factors that may be associated with ambulatory outcome following thrombolysis therapy in ischemic stroke patients with pre-stroke depression is not fully understood. This was investigated. **Methods.** Multivariate analyses were performed to identify predictors of functional ambulatory outcomes. Patient demographics and clinical risk factors served as predictive variables, while improvement or no improvement in ambulatory outcome was considered as the primary outcome. **Results.** A total of 595 of these patients received rtPA of which 310 patients presented with pre-stroke depression, 217 had no improvement in functional outcome, while 93 patients presented with an improvement in functional outcome. Carotid artery stenosis (OR= 11.577, 95% CI, 1.281 – 104.636, P=0.029) and peripheral vascular disease (OR= 18.040, 95% CI, 2.956-110.086, P=0.002) were more likely to be associated with an improvement in ambulation. Antihypertensive medications (OR= 7.810, 95% CI, 1.401 –43.529, P=0.019), previous TIA (OR= 0.444, 95% CI, 0.517 –0.971, P=0.012), and congestive heart failure (OR= 0.217, 95% CI, 0.318 –0.402, P=0.030) were associated with a no improvement in ambulation. **Conclusion.** After adjustment for covariates, more clinical risk factors were associated with no improvement when compared with improvement in functional outcome following thrombolysis therapy in an acute ischemic stroke population with pre-stroke depression.

Background

Clinical outcomes following ischemic stroke in patients with depression manifest in various forms, including ambulation, which is relevant in the assessment of treatment outcomes[1]. Ambulatory behavior is known to be modulated by emotions and has long been recognized as an integral sign of depression[2], and can predict the course of the disease[3, 4]. Alterations in the ambulatory status are well-known as clinically observable phenomena of depressed patients[5]. These alterations may be linked to abnormalities in the motor pathways that may also lead to alterations of ambulatory patterns in depressed patients[6]. Several studies [7-10] provide evidence that an improvement or lack of improvement in the ambulatory status of patients with depression is relevant for evaluation of course and treatment response[3, 4, 11]. After stroke, more than 60% of survivors present with a reduced ambulatory status[12, 13]. It is known that in ischemic stroke patients, pre-stroke clinical risk factors may predict ambulatory recovery following thrombolysis therapy[14, 15].

While post-stroke depression is a common occurrence and linked with poor outcome[16-19], the effect of pre-stroke depression on treatment outcome in ischemic stroke patients is not well understood. Pre-stroke depression may be associated with abnormal modification of risk factors in ischemic stroke[20, 21], and may affect functional ambulatory outcome following rtPA. However, clinical risk factors that may predict ambulatory outcome of ischemic stroke patients with pre-stroke depression are yet to be fully understood. We tested the hypothesis that specific clinical risk factors may be predictive of ambulatory outcome in ischemic stroke patients with pre-stroke depression treated with thrombolysis therapy. There is a likelihood that the population of ischemic stroke patients with pre-stroke depression with improvement in functional ambulation after treatment with thrombolysis therapy maybe different

from those with no improvement. In this context, there is a possibility that different clinical risk factors would be associated with improvement, when compared with no improvement in ambulatory function after rtPA in ischemic stroke patient with pre-stroke depression. The aim of this study is to identify clinical risk factors associated with ambulatory recovery in ischemic stroke patients with pre-stroke depression treated with thrombolysis therapy. Thrombolysis therapy is an FDA-approved treatment for acute ischemic stroke, and there is no clinical reason to withhold the use of rtPA based on pre-stroke depression alone. Therefore, understanding clinical risk factors that may affect ambulatory recovery in ischemic stroke patients with pre-stroke depression may help in the development of management strategies to improve the use of rtPA in ischemic stroke patients with pre-stroke depression.

Methods

2.1 *Research Design*

This study contains retrospective data obtained from a large stroke registry and was approved by the institutional Ethics Committee. Data within the Greenville Health System (GHS) stroke registry has been standardized according to the “Get with The Guidelines” (GWTG) stroke registry formed by the American Heart Association (AHA). Details in the ascertainment and data collection have previously been described [22-24]. Briefly, data was collected from 1466 ischemic stroke patients admitted to the stroke Unit of GHS between January 2014 and June 2016 with a diagnosis of acute ischemic stroke. Eligibility for rtPA was based on the AHA inclusion guidelines for early management of patients with acute ischemic stroke [25]. All cases of prospective clinical identification of acute ischemic stroke were confirmed by computed tomography (CT). Our data analysis utilized retrospective data of confirmed cases of acute ischemic stroke from the standardized registry. In this study, patients were included if they were, 1) discharged from the stroke unit of GHS between January 2014 and June 2016 with acute ischemic as their primary cause for hospitalization, 2) entered into the GWTG-Stroke registry and, 3) with documented history pre-stroke depression on admission.

We excluded patients if there was no documentation of medical history on admission, as well as patients with mild or improving stroke symptoms. Data on symptomatic hemorrhage was not included in our data collection. Our inclusion criteria allowed us to focus our analysis on ischemic stroke patients with a history of pre-stroke depression. We collected data on patient demographics, including age, sex, race (African-American/black, white or other) and Hispanic ethnicity. Information about medical history was obtained from electronic medical records, and we collected and analyzed data on clinical risk factors for stroke in patients with pre-stroke depression. Clinical risk factors include atrial fibrillation, coronary artery disease or prior myocardial infarction, carotid stenosis, drug abuse, diabetes mellitus, dyslipidemia, congestive heart failure, obesity, hypertension, peripheral vascular disease, previous stroke, transient ischemic attack (TIA), renal insufficiency, or smoking. While data from history of pre-stroke depression was abstracted from the medical record, data collected for antidepressant medication was not directly linked to pre-stroke depression for each patient. Data for use of antihypertensive medication, cholesterol reducing agents, and antihypertensive agents also collected. Medical records on hospital course, initial

NIHSS score and examination findings including weakness, aphasia, systolic and diastolic blood pressures, and status at discharge were collected. Clinical parameters relating to the hospital course included data of stroke patients in the use of rtPA for the 4.5 hours of the protocol. We included data on laboratory analyses of samples including serum lipid panel, LDL, total cholesterol and creatinine levels. Ambulatory status was characterized using a three-level tiered system at both admission and at discharge, assigning each patient to one of the following: 1) unable to ambulate, 2) able to ambulate with assistance, 3) able to ambulate independently. This allowed us to analyze changes in ambulation status from admission to discharge in patients who received rtPA, as well as identify risk factors associated with improvement or no improvement in ambulatory status.

Statistical analysis

We analyzed our data using the SPSS Statistics Software version 15.0 (Chicago, IL). We utilized descriptive statistics to characterize the demographic and clinical risk factors in ischemic stroke patients with pre-stroke depression treated with rtPA and characterize them based on improvement or no improvement in ambulatory status. We tested the normality of our data using the Kolmogorov-Smirnov test. All continuous variables were analyzed using a Student-t-test, while discrete variables were analyzed using Pearson's Chi-Squared analyses. The mean, standard deviation, and range were determined for all continuous variables and significant differences at $P < 0.05$ were determined. The number of patients and percentage of patients in each category were analyzed for all discrete variables.

We used logistic regression analysis to identify predictive clinical risk factors in a population of ischemic stroke patients with pre-stroke depression who were treated with rtPA. This sample population was then divided into two groups: improvement ambulatory status after treatment and no improvement in ambulatory status after treatment. In our logistic regression analysis, we retained parameters that the p-value were less than 0.05, and parameters with p-values > 0.05 were excluded and eliminated stepwise. We then re-considered and added parameters that were initially eliminated in the model if they met the criteria of $p < 0.05$. We adjusted for clinical covariates that were significant in the unadjusted univariate analysis using the backward elimination method with conventional P value < 0.05 .

The primary outcome of our logistic model was the identification of baseline clinical risk factors that were significantly associated with improvement or no improvement in ambulation following thrombolysis therapy in ischemic stroke patients with pre-stroke depression. This approach allowed us to identify specific clinical risk factors associated with an improvement or no improvement in ambulation recovery in the multivariate analysis. We used the variance inflation factor to determine independence of variables included in the regression model to address the issue of collinearity or interactions between independent variables. We tested the validity of our model using a Hosmer-Lemeshow test, and the overall correct classification percentage and the area under the Receiver Operating Curve (ROC) for score prediction was determined. This allowed us to test the sensitivity, specificity and accuracy of our logistic model. Odds ratios (ORs) were determined from the logistic regression and significance was set at the probability level

of 0.05. We then use the odds ratio values to predict the odds of attaining a specific ambulation outcome in ischemic stroke patients with pre-stroke depression treated with thrombolysis therapy.

Discussion

The goal of this study was to investigate clinical risk factors that may be associated with an improvement or no improvement in the recovery of ambulatory functions following thrombolysis therapy in acute ischemic stroke patients with pre-stroke depression. In the univariate analysis, we found that the proportion of ischemic stroke patients with pre-stroke depression who presented with no improvement in ambulation after treatment with rtPA was higher than those with an improvement in ambulation. This may be linked to differences in the proportion of clinical factors between patients that presented with an improvement and those with no improvement in their ambulation status. We expected that the use of antidepressants would be identified as a variable associated with ambulatory status. However, the univariate analysis as well as the adjusted analysis did not reveal a significant association of antidepressants with ambulatory outcome in ischemic stroke patients with pre-stroke depression treated with thrombolysis therapy. It is possible that the variation in the effects or use of antidepressants may be associated with stroke severity, rather than with the ambulation status.

In the univariate analysis, NIHSS (indicator of stroke severity) was associated with a significant improvement in ambulation among ischemic stroke patients with pre-stroke depression. This effect was sustained in the adjusted analysis for the total population of ischemic stroke patients with pre-stroke depression and was associated with no improvement in the group with no improvement in ambulation following rtPA. In general, the initial NIHSS score is a strong predictor of stroke severity and may predict functional outcome as well. In the univariate analysis, stroke severity, demonstrated by NIHSS, was between 0 and 14 for many of the patients with no improvement following treatment with rtPA. The adjusted analysis associated initial NIHSS with both an improvement and no improvement in ambulation following rtPA. This finding indicates that the severity of stroke is not enough to predict functional ambulatory outcomes, and that clinical risk factors may as well play a significant role [26, 27].

In the population that presented with an improvement in ambulation, we observed that in the adjusted analysis, patients that presented with carotid artery stenosis and peripheral vascular disease were more likely to be associated with an improvement in ambulation. However, patients that took antihypertensive medications were more likely to be associated with no improvement following thrombolysis therapy. Because clinical risk factors associated with an improvement in functional ambulatory recovery may be different between the population with an improvement and those with no improvement, we performed additional analyses to evaluate if these factors may significantly differ. Our findings indicate that in the no improvement group, the effect of carotid artery disease and peripheral vascular disease, which were significant in the improvement group, were attenuated in the no improvement group. Moreover, our adjusted analysis revealed that previous TIA, congestive heart disease, and use of antihypertensive

medications were more likely to be significantly associated with no improvement in functional ambulatory recovery in ischemic stroke patients with pre-stroke depression.

Previous TIA is not a formal contraindication for rtPA, especially if the TIA was at least three months before the onset of stroke [28] [22, 29]. However, it has been shown that the onset of TIA within 24 hours of stroke may lead to a poor outcome following rtPA [30, 31]. It is possible that some ischemic stroke patients with pre-stroke depression may present an invisible TIA in the CT scans making it difficult to detect, and this may affect treatment outcome with rtPA. This might be the case in ischemic stroke patients with pre-stroke depression that received rtPA resulting in no improvement outcome in functional ambulatory recovery. The association between antihypertensive medication and depression is well documented in the literature [32, 33]. It is known that if depression occurs prior to stroke, medication use plays a role in the treatment outcome of the stroke [21, 34]. It is also known that clinical risk factors contribute to, or worsen, the underlying disease such as depression and stroke [28]. However, the relationship between certain clinical risk factors, such as congestive heart failure, with treatment response to rtPA and functional ambulatory outcome in ischemic stroke patients with pre-stroke depression is not known.

Depression is an independent risk factor for the onset of congestive heart failure [35, 36], and subclinical depressive symptoms are also correlated with an increased risk of stroke [37]. The biological variables that trigger this relationship are due to multiple alterations in neuroimmunoendocrine proteins in depressed patients, especially in the acute phase [38]. It is not clear how these factors interact with rtPA to affect functional ambulatory recovery in ischemic stroke patients with pre-stroke depression, and this is beyond the scope of the current study. However, ample evidence indicates that congestive heart failure may have a causal relationship with depression in stroke patients [39-42]. This is especially important since certain areas in the brain, including the medial temporal region, an area associated with the pathophysiology of depression, are particularly vulnerable to perfusion deficits which arise in the context of congestive heart failure [43, 44]. Clinically, our results indicate that congestive heart failure, antihypertensive medications, and previous TIA are important clinical risk factors that may affect the treatment outcomes of thrombolysis therapy and affect functional ambulatory recovery in ischemic stroke patients with pre-stroke depression. Our findings have practical implications and suggest the need for the development of an effective strategy to manage the combined effect of congestive heart failure, antihypertensive medications, and TIA in ischemic stroke patients with pre-stroke depression.

Our study has limitations. The retrospective nature of our data may indicate the possibility of selection bias. In addition, the absence of pre-stroke functional status data including pre-stroke mRS and post treatment NIHSS scores did not allow for the comparison of ambulatory recovery and NIHSS scores or mRS to be evaluated. Depression is a common post-stroke complication and pre-stroke depression is known to contribute to treatment outcome following thrombolysis therapy. An important contribution of the current study to existing literature is identification of specific clinical risk factors that are significantly associated with functional ambulatory outcome in ischemic stroke patient with incidence of pre-stroke depression who received thrombolysis therapy.

Conclusions

In this study, we have shown that few acute ischemic stroke patients with pre-stroke depression received rtPA, and more clinical risk factors were associated with no improvement in functional outcome when compared with those that were associated an improvement in ambulation among ischemic stroke patients with a history of pre-stroke depression. Our findings reveal that congestive heart failure, antihypertensive medications, and previous TIA are significant clinical risk factors that may affect the treatment outcomes of thrombolysis therapy in ischemic stroke patients with a history of pre-stroke depression. Future studies should focus on effective strategies to manage these clinical risk factors to improve treatment outcomes of thrombolytic therapy in ischemic stroke patients with pre-stroke depression.

References

1. Bennabi D, Vandel P, Papaxanthis C, Pozzo T, Haffen E: **Psychomotor Retardation in Depression: A Systematic Review of Diagnostic, Pathophysiologic, and Therapeutic Implications.** *Biomed Research International* 2013, **4**:1-18.
2. Jacob GA, Zvonik K, Kamphausen S, Sebastian A, Maier S, Philipsen A, van Elst LT, Lieb K, Tuscher O: **Emotional modulation of motor response inhibition in women with borderline personality disorder: an fMRI study.** *Journal of Psychiatry & Neuroscience* 2013, **38**(3):164-172.
3. Sobin C, Sackeim HA: **Psychomotor symptoms of depression.** *American Journal of Psychiatry* 1997, **154**(1):4-17.
4. Walther S, Bernard JA, Mittal VA, Shankman SA: **The utility of an RDoC motor domain to understand psychomotor symptoms in depression.** *Psychological Medicine* 2019, **49**(2):212-216.
5. Miller GE, Cohen S, Herbert TB: **Pathways linking major depression and immunity in ambulatory female patients.** *Psychosomatic Medicine* 1999, **61**(6):850-860.
6. Bracht T, Federspiel A, Schnell S, Horn H, Hofle O, Wiest R, Dierks T, Strik W, Muller TJ, Walther S: **Cortico-Cortical White Matter Motor Pathway Microstructure Is Related to Psychomotor Retardation in Major Depressive Disorder.** *PloS one* 2012, **7**(12).
7. Lemke MR, Wendorff T, Mieth B, Buhl K, Linnemann M: **Spatiotemporal gait patterns during over ground locomotion in major depression compared with healthy controls.** *Journal of Psychiatric Research* 2000, **34**(4-5):277-283.
8. Bewernick BH, Urbach AS, Broder A, Kayser S, Schlaepfer TE: **Walking away from depression-motor activity increases ratings of mood and incentive drive in patients with major depression.** *Psychiatry Research* 2017, **247**:68-72.
9. Lemke MR: **Motor phenomena in depression.** *Nervenarzt* 1999, **70**(7):600+.
10. Razavi N, Horn H, Koschorke P, Hugli S, Hofle O, Muller T, Strik W, Walther S: **Measuring motor activity in major depression: The association between the Hamilton Depression Rating Scale and actigraphy.** *Psychiatry Research* 2011, **190**(2-3):212-216.

11. Hoepfner J, Padberg F, Domes G, Zinke A, Herpertz SC, Grossheinrich N, Herwig U: **Influence of repetitive transcranial magnetic stimulation on psychomotor symptoms in major depression.** *European Archives of Psychiatry and Clinical Neuroscience* 2010, **260**(3):197-202.
12. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS: **RECOVERY OF WALKING FUNCTION IN STROKE PATIENTS - THE COPENHAGEN STROKE STUDY.** *Archives of Physical Medicine and Rehabilitation* 1995, **76**(1):27-32.
13. Kwakkel G, Kollen BJ: **Predicting activities after stroke: what is clinically relevant?** *International Journal of Stroke* 2013, **8**(1):25-32.
14. Malsch C, Liman T, Wiedmann S, Siegerink B, Georgakis MK, Tiedt S, Endres M, Heuschmann PU: **Outcome after stroke attributable to baseline factors-The PROSpective Cohort with Incident Stroke (PROSCIS).** *PloS one* 2018, **13**(9).
15. Gainey J, Brechtel J, Blum B, Keels A, Madeline L, Lowther E, Nathaniel IT: **Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology.** *Journal of Experimental Neuroscience* 2018, **12**:1-11.
16. Baccaro A, Wang YP, Candido M, Conforto AB, Brunoni AR, Leite CD, Busatto G, Lotufo PA, Bensenor IM, Goulart AC: **Post-stroke depression and cognitive impairment: Study design and preliminary findings in a Brazilian prospective stroke cohort (EMMA study).** *Journal of Affective Disorders* 2019, **245**:72-81.
17. Li JF, Li Y, Li P, Ye MY: **Early Symptom Measurement of Post-Stroke Depression: Development and validation of a new short version.** *Journal of Advanced Nursing* 2019, **75**(2):482-493.
18. Wilkins SS, Akhtar N, Salam A, Bourke P, Joseph S, Santos M, Shuaib A: **Acute post stroke depression at a Primary Stroke Center in the Middle East (vol 13, e0208708, 2018).** *PloS one* 2019, **14**(2).
19. Yildirim MA, Ones K: **Post stroke depression and related factors.** *Dusunen Adam-Journal of Psychiatry and Neurological Sciences* 2019, **32**(1):52-57.
20. Cai W, Mueller C, Li YJ, Shen WD, Stewart R: **Post stroke depression and risk of stroke recurrence and mortality: A systematic review and meta-analysis.** *Ageing Research Reviews* 2019, **50**:102-109.
21. Taylor-Rowan M, Momoh O, Ayerbe L, Evans JJ, Stott DJ, Quinn TJ: **Prevalence of pre-stroke depression and its association with post-stroke depression: a systematic review and meta-analysis.** *Psychological Medicine* 2019, **49**(4):685-696.
22. Nathaniel TI, Cochran T, Chaves J, Fulmer E, Sosa C, Yi S, Fredwall M, Sternberg S, Blackhurst D, Nelson A *et al.*: **Co-morbid conditions in use of recombinant tissue plasminogen activator (rt-PA) for the treatment of acute ischaemic stroke.** *Brain injury* 2016, **30**(10):1261-1265.
23. Colello MJ, Ivey LE, Gainey J, Faulkner RV, Johnson A, Brechtel L, Madeline L, Nathaniel TI: **Pharmacological thrombolysis for acute ischemic stroke treatment: Gender differences in clinical risk factors.** *Advances in Medical Sciences* 2018, **63**(1):100-106.
24. Gainey J, Brechtel L, Konklin S, Madeline L, Lowther E, Blum B, Nathaniel TI: **In a stroke cohort with incident hypertension; are more women than men likely to be excluded from recombinant tissue-type Plasminogen Activator (rtPA)?** *Journal of the neurological sciences* 2018, **387**:139-146.

25. Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, Ellrodt G, Cannon CP, Liang L, Peterson E *et al*: **Get With the Guidelines-Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack.** *Circulation* 2009, **119**(1):107-U206.
26. Zhang S, Liu Z, Liu YL, Wang YL, Liu T, Cui XB: **Prevalence of stroke and associated risk factors among middle-aged and older farmers in western China.** *Environmental Health and Preventive Medicine* 2017, **22**(1).
27. Madsen TE, Khoury JC, Alwell KA, Moomaw CJ, Kissela BM, De Los Rios La Rosa F, Woo D, Adeoye O, Flaherty ML, Khatri P *et al*: **Analysis of tissue plasminogen activator eligibility by sex in the Greater Cincinnati/Northern Kentucky Stroke Study.** *Stroke* 2015, **46**(3):717-721.
28. Sobolewski P, Broła W, Wiszniewska M, Szczuchniak W, Fudala M, Domagalski M, Sledzinska-Dzwigal M: **Intravenous thrombolysis with rt-PA for acute ischemic stroke within 24 h of a transient ischemic attack.** *Journal of the neurological sciences* 2014, **340**(1-2):44-49.
29. Nathaniel IT, Gainey J, Blum B, Montgomery C: **Clinical Risk Factors in Thrombolysis therapy: Telestroke Versus Nontelestroke.** *Journal of stroke and Cerebrovascular Disease* 2018.
30. Akijian L, Ni Chroinin D, Callaly E, Hannon N, Marnane M, Merwick A, Sheehan O, Hayden D, Horgan G, Duggan J *et al*: **Why do transient ischemic attack patients have higher early stroke recurrence risk than those with ischemic stroke? Influence of patient behavior and other risk factors in the North Dublin Population Stroke Study.** *International Journal of Stroke* 2017, **12**(1):96-104.
31. Tursunov D, Akbarkhodjaeva Z: **Risk factors of developing transient ischemic attack.** *Journal of the neurological sciences* 2017, **381**:1115-1115.
32. Demirturk E, Asilar RH: **The effect of depression on adherence to antihypertensive medications in elderly individuals with hypertension.** *Journal of Vascular Nursing* 2018, **36**(3):129-139.
33. Hamieh N, Meneton P, Wiernik E, Limosin F, Zins M, Goldberg M, Melchior M, Lemogne C: **Depression, treatable cardiovascular risk factors and incident cardiac events in the Gazel cohort.** *International Journal of Cardiology* 2019, **284**:90-95.
34. Wilkins SS, Akhtar N, Salam A, Bourke P, Joseph S, Santos M, Shuaib A: **Acute post stroke depression at a Primary Stroke Center in the Middle East.** *PloS one* 2018, **13**(12).
35. Chaturvedi A, Joshi A, Chandrika P, Sharma T, Castagnaro M, Alpert C, Poornima I, Raina A: **INCREASED CLINICAL BURDEN OF HEART FAILURE IN PATIENTS WITH DEPRESSION: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE DATABASE.** *Journal of the American College of Cardiology* 2019, **73**(9):915-915.
36. Prabhakar P, Allen KS, Carter VM, Wirth DL, Quest TE, Ogunniyi MO, Lal AA: **DEPRESSION SCREENING IN A SAFETY-NET HEART FAILURE CLINIC: LESSONS LEARNED.** *Journal of the American College of Cardiology* 2019, **73**(9):859-859.
37. Everson SA, Roberts RE, Goldberg DE, Kaplan GA: **Depressive symptoms and increased risk of stroke mortality over a 29-year period.** *Archives of Internal Medicine* 1998, **158**(10):1133-1138.

38. Antonioli M, Rybka J, Carvalho LA: **Neuroimmune endocrine effects of antidepressants.** *Neuropsychiatric Disease and Treatment* 2012, **8**:65-83.
39. Daskalopoulou M, George J, Walters K, Osborn DP, Batty GD, Stogiannis D, Rapsomaniki E, Pujades-Rodriguez M, Denaxas S, Udumyan R *et al*: **Depression as a Risk Factor for the Initial Presentation of Twelve Cardiac, Cerebrovascular, and Peripheral Arterial Diseases: Data Linkage Study of 1.9 Million Women and Men.** *PloS one* 2016, **11**(4).
40. Dhar AK, Barton DA: **Depression and the Link with Cardiovascular Disease.** *Frontiers in Psychiatry* 2016, **7**.
41. Bangalore S, Shah R, Pappadopulos E, Deshpande CG, Shelbaya A, Prieto R, Stephens J, McIntyre RS: **Cardiovascular hazards of insufficient treatment of depression among patients with known cardiovascular disease: a propensity score adjusted analysis.** *European Heart Journal-Quality of Care and Clinical Outcomes* 2018, **4**(4):258-266.
42. Patel RS, Shrestha S, Saeed H, Raveendranathan S, Isidahome EE, Ravat V, Fakorede MO, Patel V: **Comorbidities and Consequences in Hospitalized Heart Failure Patients with Depression.** *Cureus* 2018, **10**(8).
43. Yeswanthi K, Aswani B, Vijayasanthi P, Lavanya K, Prasanth B: **A REVIEW ON DEPRESSION - POST STROKE COMPLICATION.** *Indo American Journal of Pharmaceutical Sciences* 2016, **3**(10):1203-1209.
44. Alves TC, Rays J, Fraguas R, Wajngarten M, Telles RMS, Souza D: **Association between major depressive symptoms in heart failure and impaired regional cerebral blood flow in the medial temporal region: a study using 99tc-HMPAO single photon emission computerized tomography (SPECT).** *Psychological Medicine* 2006, **36**:597-608.

Declarations

Ethics approval and consent to participate: This study was performed with the approval of the Institutional Review Board of Greenville Health System and the institutional Committee for Ethics. Being a retrospective data analysis with blinded data, no consent was needed.

Consent for Publication: Not applicable.

Availability of data and materials. All materials are available for use from the corresponding author.

Competing interests: Authors report no conflict of interest

Funding: This study was funded by the Fullerton Foundation.

Authors' contribution. LW, BB, BB and TIN designed the concept, experimental design and data analysis, while TIN critically revised the drafts read and approved the last version of this manuscript. All authors have provided the corresponding author with permission to be named in the manuscript and approved the submission of this manuscript.

Acknowledgement. We thank the stroke unit of Greenville Health system for helping in the data collection.

Conflict of interest: None

Dr Thomas Nathaniel is an associate Editor for BMC Neurology.

Tables

Due to technical limitations, the tables have been placed in the Supplementary Files section.

Table Captions:

Table 1: Demographic and clinical characteristics of ischemic stroke patients with pre-stroke depression. Results for continuous variables are presented as Mean \pm S.D, while discrete data are presented percentage frequency. Pearson's Chi-Squared is used compare differences between improvement and no improvement in ambulatory outcome in rtPA treated groups.

Table 2: Results for the logistic regression model that predicts clinical risk factors associated with improvement or no improvement in ambulatory recovery for an ischemic stroke population with pre-stroke depression. Adjusted OR<1 indicates clinical and demographic factors associated with no improvement in ambulation while Adjusted OR>1 reveal factor associated an improvement in ambulation following thrombolysis therapy. Hosmer-Lemeshow test, Cox & Snell ($R^2=0.0.707$), and the overall classified percentage of 70.7% was applied to check the model fitness. * Indicates statistical significance ($P<0.05$) with 95% a confidence interval.

Table 3. Predictive clinical and demographic variables associated with an improvement in ambulation for ischemic stroke population with pre-stroke depression, treated with rtPA. Adjusted OR<1 denote factors that are associated with no improvement in ambulation while adjusted OR>1 denote factors that are associated with an improvement in ambulation. Hosmer-Lemeshow test, Cox & Snell ($R^2=0.827$). The overall classified percentage of 82.7% was applied to check for the fitness of the logistic regression model. * Indicates statistical significance ($P<0.05$) with 95% a confidence interval.

Table 4. Clinical factors that were associated with no improvement in ambulation for ischemic stroke population with pre-stroke depression treated with rtPA. Adjusted OR<1 indicates factors associated with no improvement while adjusted OR>1 indicates factors associated with an improvement. Hosmer-Lemeshow test, Cox & Snell ($R^2=0.842$), and the overall classified percentage of 84.2% was applied to check for the fitness of the logistic regression model. * Indicates statistical significance ($P<0.05$) with 95% a confidence interval.

Figures




Figure 1

The Receiver Operating Curve (ROC) of ambulation for the logistic regression model for ischemic stroke patients with pre-stroke depression treated with rtPA. The model shows a good discriminating ability with area under the curve (AUROC= 0.707, 95% CI, 0.639-0.776, $P < 0.001$).




Figure 2

The Receiver Operating curve (ROC) curve for predictive clinical and demographic variables associated with an improvement in ambulation for ischemic stroke population with pre-stroke depression treated with rtPA. The model shows a strong discriminating ability with area under the curve (AUROC= 0.827,95% CI, 0.759-0.895, P<0.001).




Figure 3

The Receiver Operating curve (ROC) curve for predictive clinical and demographic variables associated with no improvement in ambulation for an ischemic stroke population with pre-stroke depression treated with rtPA. The model shows a strong discriminating ability with area under the curve (AUROC= 0.842,95% CI, 0.778-0.906, P<0.001).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Table3.png](#)
- [Table4.png](#)
- [Table1.png](#)
- [Table2.png](#)